6533b826fe1ef96bd128539d

RESEARCH PRODUCT

False-positive LSD testing in urine samples from intensive care patients.

T KernJ. RöhrichS. ZörntleinJ LotzJürgen Prof. Dr. BeckerC. Rittner

subject

HallucinogenAdultMalemedicine.medical_specialtyHealth Toxicology and MutagenesisAmbroxolUrineCross ReactionsToxicologyHigh-performance liquid chromatographyGastroenterologyAnalytical Chemistrylaw.inventionlawIntensive careInternal medicinemedicineEnvironmental ChemistryHumansFalse Positive ReactionsChromatography High Pressure LiquidLysergic acid diethylamideAgedExpectorantsAged 80 and overImmunoassayChemical Health and SafetyChromatographymedicine.diagnostic_testChemistryIntensive care unitAmbroxolIntensive Care UnitsLysergic Acid DiethylamideImmunoassayHallucinogensFemaleReagent Kits Diagnosticmedicine.drug

description

Unexpected positive results for lysergic acid diethylamide (LSD) were found in urine samples from 12 patients in an intensive care unit in a routine screening using the CEDIA DAU assay. None of these test results could be confirmed by high-performance liquid chromatography analysis, but all samples contained the mucolytic drug ambroxol. Further studies demonstrated that ambroxol exhibits a significant cross-reactivity in the CEDIA DAU LSD assay. Therefore, positive LSD results obtained with the CEDIA DAU assay have to be critically evaluated, particularly during the cold season, when infections of the respiratory tract often result in more frequent use of mucolytic medications.

yearjournalcountryeditionlanguage
1998-09-16Journal of analytical toxicology
10.1093/jat/22.5.393https://pubmed.ncbi.nlm.nih.gov/9737335